Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results
| Title: | Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results |
|---|---|
| Authors: | Ewa Wąsik-Szczepanek, Agnieszka Szymczyk, Małgorzata Kowal, Adam Nogalski, Marek Hus |
| Source: | Annals of Agricultural and Environmental Medicine, Vol 25, Iss 1, Pp 56-59 (2018) |
| Publisher Information: | Institute of Rural Health, 2018. |
| Publication Year: | 2018 |
| Collection: | LCC:Agriculture LCC:Environmental sciences |
| Subject Terms: | chronic lymphocytic leukemia, ofatumumab, monoclonal antibodies, immunotherapy, Agriculture, Environmental sciences, GE1-350 |
| More Details: | Introduction Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Material and Methods The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1232-1966 1898-2263 12321966 |
| Relation: | http://www.journalssystem.com/aaem/Assessment-of-the-efficacy-of-ofatumumab-in-patients-with-chronic-lymphocytic-leukaemia-treated-in-the-Department-of-Haematooncology-and-Bone-Marrow-Transplantation-of-the-Medical-University-in-Lublin-Prelimary-results,72501,0,2.html; https://doaj.org/toc/1232-1966; https://doaj.org/toc/1898-2263 |
| DOI: | 10.5604/12321966.1233571 |
| Access URL: | https://doaj.org/article/b8884dad74de45b7bef0ca6a372c28da |
| Accession Number: | edsdoj.b8884dad74de45b7bef0ca6a372c28da |
| Database: | Directory of Open Access Journals |
| ISSN: | 12321966 18982263 |
|---|---|
| DOI: | 10.5604/12321966.1233571 |
| Published in: | Annals of Agricultural and Environmental Medicine |
| Language: | English |